Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

Morgan Stanley analyst Kallum Titchmarsh has upgraded West Pharmaceutical Services (NYSE: WST) from Equal-Weight to Overweight. The price target for the stock has been raised from $365 to $400.